Skip to main content
Kidney360 logoLink to Kidney360
. 2022 Jan 4;3(3):488–496. doi: 10.34067/KID.0006932021

Initial Home Dialysis Is Increased for Rural Patients by Accessing Urban Facilities

Joel T Adler 1,2,, S Ali Husain 3,4, Lingwei Xiang 2, James R Rodrigue 5, Sushrut S Waikar 6
PMCID: PMC9034801  PMID: 35582180

Key Points

  • Despite having access to fewer facilities that offer home dialysis, rural patients with ESKD are more likely to be on home dialysis.

  • There remains a significant mortality gap between urban and rural patients with ESKD, even when accessing home dialysis.

Keywords: dialysis, chronic kidney disease, clinical nephrology, home dialysis, mortality gap, rural population, urban facilities

Visual Abstract

graphic file with name KID.0006932021absf1.jpg

Abstract

Background

The 240,000 rural patients with end stage kidney disease in the United States have less access to nephrology care and higher mortality than those in urban settings. The Advancing American Kidney Health initiative aims to increase the use of home renal replacement therapy. Little is known about how rural patients access home dialysis and the availability and quality of rural dialysis facilities.

Methods

Incident dialysis patients in 2017 and their facilities were identified in the United States Renal Data System. Facility quality and service availability were analyzed with descriptive statistics. We assessed the availability of home dialysis methods, depending on rural versus urban counties, and then we used multivariate logistic regression to identify the likelihood of rural patients with home dialysis as their initial modality and the likelihood of rural patients changing to home dialysis within 90 days. Finally, we assessed mortality after dialysis initiation on the basis of patient home location.

Results

Of the 97,930 dialysis initiates, 15,310 (16%) were rural. Rural dialysis facilities were less likely to offer home dialysis (51% versus 54%, P<0.001). Although a greater proportion of rural patients (9% versus 8%, P<0.001) were on home dialysis, this was achieved by traveling to urban facilities to obtain home dialysis (OR=2.74, P<0.001). After adjusting for patient and facility factors, rural patients had a higher risk of mortality (HR=1.06, P=0.004).

Conclusions

Despite having fewer facilities that offer home dialysis, rural patients were more often on home dialysis methods because they traveled to urban facilities, representing an access gap. Even if rural patients accessed home dialysis at urban facilities, rural patients still suffered worse mortality. Future dialysis policy should address this access gap to improve care and overall mortality for rural patients.

Introduction

The 2019 federal Advancing American Kidney Health (AAKH) initiative set the goal of 80% of incident ESKD patients receiving home RRT or undergoing kidney transplantation by 2025 (1). Although delayed in implementation, this remains an important lens for ESKD policy evaluation. Attaining these goals is ambitious and faces a significant obstacle: of the 131,636 incident ESKD patients in 2018, only 14,334 (11%) started on peritoneal dialysis, 443 (0.3%) started on home hemodialysis, and 3854 (3%) underwent kidney transplantation (2). Achieving these goals therefore requires improving the quality of care of the ESKD population (3) by addressing pervasive health care disparities and inequities that limit access to these treatment modalities (46).

The role of these disparities in a rural ESKD population is understudied (7). In general, rural patients have less access to primary care (8) and specialist (9) physicians, and they have a higher population mortality due to lower overall socioeconomic status, health care provider shortages, and lower rates of health insurance (10). Compared with their urban counterparts, the 240,000 rural patients with ESKD in the United States have less access to predialysis nephrology care, suffer higher mortality on dialysis, and are less likely to receive or be evaluated for kidney transplantation (11). Although rural patients with ESKD are more often on home RRT, the supply of peritoneal dialysis providers in rural areas has only modestly increased over the past decade (12), thereby impairing the expansion of access to home RRT (1315).

Due to these disparities, patients with ESKD may benefit less from AAKH initiatives and from dialysis policy changes more generally. The role and quality of rural dialysis facilities, and which facilities patients have access to, is not well understood. To understand better the available dialysis facilities, their characteristics, and the likelihood of starting on home RRT, we undertook this study to assess the relationship of patient rurality, dialysis facility location, home dialysis use, and patient mortality for the initiating dialysis cohort in 2017.

Materials and Methods

Data Sources

The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government. Dialysis facility characteristics were obtained from Medicare Dialysis Facility Compare (16). The data that support the findings of this study are available from the corresponding author upon reasonable request, and the manuscript complies with STROBE guidelines for cohort studies.

Study Cohort

The study cohort consisted of all adult (≥18 years of age) patients beginning chronic dialysis for the first time in the United States in 2017 with follow-up through the end of 2018. We then matched Dialysis Facility Compare data from 2017 to the USRDS cohort to enhance the description of the cohort, dialysis facility characteristics, and quality measures.

Variable Definitions

Rurality was defined for both patients and dialysis centers on the basis of the county in which they were located. Using the Urban Influence Code (https://www.ers.usda.gov/data-products/urban-influence-codes/documentation.aspx), counties were categorized as urban (categories 1 and 2) or rural (categories 3–12). This also matches the federal Office of Management and Budget definition of counties being either metropolitan or nonmetropolitan/rural. Dialysis facility size was divided into small (≤10 stations), medium (11–30 stations), and large (≥31 stations). We also grouped dialysis facilities by the type of ownership: large chains (Fresenius and DaVita facilities), small chains (all others in a chain), and independent facilities.

Outcomes and Statistical Analyses

Categorical variables are described using frequencies and percentages. Continuous measures are described using median and interquartile range (IQR). Pearson chi-squared test and Kruskal–Wallis test were performed to determine the unadjusted associations as appropriate. An α level of 0.05 was used as the criterion for statistical significance. No adjustments were made for multiple comparisons.

The three primary outcomes, with rurality as main covariate of interest, were (1) the likelihood of home dialysis as the initial dialysis modality, (2) the likelihood of switching dialysis modality in the first 90 days, and (3) all-cause mortality after dialysis initiation. Covariates in the models were chosen for their clinical and policy significance. Results are presented as fully adjusted models with patient- and facility-level covariates. Logistic regression was used for initial dialysis modality, switching within 90 days, and for being on home dialysis at facilities that offer home dialysis. The survival analysis was conducted for patient mortality after dialysis initiation using Cox proportional hazard models. Patients who were alive until the last day of follow-up or the end of 2018 were censored.

All statistical analyses and data linkages were performed using SAS v9.4 (SAS Institute, Cary, NC). Map was made with QGIS v3.12 (QGIS Development Team, Open Source Geospatial Foundation Project; http://qgis.osgeo.org).

Results

Patient and Dialysis Facility Characteristics Vary by Urban and Rural Location

A total of 97,930 patients initiated dialysis in 2017, among whom 15,310 (16%) were from rural counties and 82,620 (84%) were from urban counties. The rural and urban populations had several clinically relevant differences (Table 1). Rural patients were more often White (70% versus 50%, P<0.001) and obese (47% versus 41%, P<0.001). Although only 949 (1%) of urban patients used a rural dialysis facility, 3293 (22%) of rural patients used an urban dialysis facility (P<0.001). Finally, a greater proportion of rural patients had home dialysis as their initial modality (9% versus 8%, P<0.001).

Table 1.

Characteristics of patients beginning dialysis in 2017

Covariate Total (N=97,930; 100%) Urban (N=82,620; 84%) Rural (N=15,310; 16%) P Value
Men, n (%) 56,457 (58) 47,747 (58) 8710 (57) 0.04a
Age, yr, median (IQR) 66 (55–75) 66 (55–75) 66 (56–74) 0.81b
Race, n (%) <0.001a
 White 52,007 (53) 41,291 (50) 10,716 (70)
 Black 25,662 (26) 22,793 (28) 2869 (19)
 Hispanic 13,863 (14) 12,918 (16) 945 (6)
 Other 6395 (7) 5615 (7) 780 (5)
 Missing 3 (0) 3 (0)
Primary disease, n (%) <0.001a
 Cystic kidney 1617 (2) 1313 (2) 304 (2)
 Diabetes 48,916 (50) 40,996 (50) 7920 (52)
 Glomerulonephritis 6168 (6) 5184 (6) 984 (6)
 Hypertension 29,742 (30) 25,566 (31) 4176 (27)
 Urologic 1344 (1) 1094 (1) 250 (2)
 Other 10,143 (10) 8467 (10) 1676 (11)
BMI, kg/m2, n (%) <0.001a
 Underweight (<18.5) 2853 (3) 2478 (3) 375 (2)
 Normal weight (18.5–25) 26,372 (27) 22,789 (28) 3583 (23)
 Overweight (25–30) 27,101 (28) 22,955 (28) 4146 (27)
 Obese (≥ 30) 41,252 (42) 34,110 (41) 7142 (47)
 Missing 352 (0.4) 288 (0.3) 64 (0.4)
Employment status, n (%) <0.001a
 Employed 10,323 (11) 9100 (11) 1223 (8)
 Retired 59,532 (61) 49,596 (60) 9936 (65)
 Unemployed 28,075 (29) 23,924 (29) 4151 (27)
Facility type, n (%) <0.001a
 Rural 12,941 (13) 924 (1) 12,017 (79)
 Urban 84,989 (87) 81,696 (99) 3293 (22)
Comorbidities, n (%)
 Amputation 3593 (4) 2935 (4) 658 (4) <0.001a
 Atherosclerotic heart disease 13,135 (13) 10,688 (13) 2447 (16) <0.001a
 Cancer 7055 (7) 5895 (7) 1160 (8) 0.05a
 Congestive heart failure 29,487 (30) 24,512 (30) 4975 (33) <0.001a
 Chronic obstructive pulmonary disease 9840 (10) 7707 (9) 2133 (14) <0.001a
 Diabetes with insulin 43,206 (44) 35,984 (44) 7222 (47) <0.001a
 Diabetes without insulin 7093 (7) 5933 (7) 1160 (8) 0.08a
 Hypertension 86,476 (88) 72,999 (88) 13,477 (88) 0.23a
 Peripheral vascular disease 9427 (10) 7600 (9) 1827 (12) <0.001a
Informed of transplantation, n (%) 85,833 (88) 72,566 (87.8) 13,267 (87) <0.001a
Initial dialysis modality, n (%) <0.001a
 In-center 89,764 (92) 75,864 (92) 13,900 (91)
 Home hemodialysis 348 (0.4) 311 (0.4) 37 (0.2)
 Peritoneal dialysis 7814 (8) 6442 (8) 1372 (9)

Percentages may not total 100 due to rounding. IQR, interquartile range; BMI, body mass index.

a

Chi-squared test.

b

Wilcoxon two-sample test.

Dialysis facilities also varied considerably between urban and rural locations (Table 2). Of the 5884 facilities, 1050 (18%) were in rural counties. Rural facilities were more likely to be small or medium-sized (97% versus 93%) facilities (P<0.001). They were less likely to offer peritoneal dialysis (51% versus 54%, P=0.04; map in Figure 1), and among those facilities that offered it, there was a lower median percentage of rural patients on home dialysis compared with their urban counterparts (12.8% versus 13.4%, P=0.03). Although rural dialysis facilities were less likely to be for-profit (86% versus 91%, P<0.001), there was no association with rurality and chain ownership (P=0.97).

Table 2.

Dialysis facility characteristics by rurality in 2017

Covariate Total (N=5884; 100%) Urban (N=4834; 82%) Rural (N=1050; 18%) P Value
Facility size (stations), n (%) <0.001b
 Small (≤10) 683 (12) 444 (9) 239 (23)
 Medium (11–30) 4809 (82) 4033 (83) 776 (74)
 Large (≥31) 392 (7) 357 (7) 35 (3)
Total patients at end of year, median (IQR) 66 (42–99) 72 (46–105) 44 (30–63) <0.001b
Patients on home dialysis, % (IQR)c 13.3 (2.9–23.9) 13.4 (2.7–24.5) 12.8 (3.7–21.7) 0.03
Offers peritoneal dialysis, n (%) 3153 (54) 2613 (54) 540 (51.4) 0.04
Organization type, n (%) <0.001a
 For-profit 5304 (90) 4406 (91) 898 (86)
 Nonprofit 580 (10) 428 (9) 152 (15)
Dialysis chain, n (%) 0.97a
 Large chain 4486 (76) 3685 (76) 801 (76)
 Small/regional chain 631 (11) 517 (11) 114 (11)
 Independent 767 (13) 632 (13) 135 (13)
Dialysis facility compare data
 Five-star rating, n (%) <0.001b
  1 137 (2) 130 (3) 7 (0.7)
  2 437 (7) 389 (8) 48 (5)
  3 2052 (35) 1761 (36) 291 (28)
  4 1662 (28) 1387 (29) 275 (26)
  5 1596 (27) 1167 (24) 429 (41)
 Hospitalization rate (per 100 patient-years), median (IQR) 179.5 (151.1–211) 184.5 (157.1–215.2) 155.1 (130.9–185.7) <0.001b
 Readmission rate (% of hospital discharges), median (IQR) 26.8 (22.1–31.5) 27.1 (22.6–31.8) 25.0 (19.5–29.6) <0.001b
 Mortality rate (per 100 patient-years), median (IQR) 21.2 (17.9–24.8) 21.1 (17.9–24.8) 21.3 (18.0–24.8) 0.41b
 Standard infection ratio, median (IQR) 0.7 (0.3–1.2) 0.7 (0.3–1.1) 0.7 (0.3–1.2) 0.25b
 Transfusion rate (per 100 patient-years), median (IQR) 18.0 (9.4–28.9) 17.9 (9.4–28.3) 18.3 (9.4–31.8) 0.10b
 Fistula rate (% of patient-months), median (IQR) 64.3 (57.2–70.7) 64.0 (57.1–70.4) 65.4 (58.0–72.5) <0.001b
Provider characteristics, median (IQR)
 Nurses per facility 4 (3–6) 4 (3–7) 3 (2–5) <0.001b
 Nurse/patient ratio 0.07 (0.05–0.09) 0.06 (0.05–0.09) 0.08 (0.06–0.10) <0.001b
 Social workers per facility 1 (1–1) 1 (1–1) 1 (1–1) <0.001b
 Social worker/patient ratio 0.02 (0.01–0.03) 0.02 (0.01–0.02) 0.02 (0.02–0.04) <0.001b

Percentages may not total 100 due to rounding. IQR, interquartile range.

a

Chi-squared test.

b

Wilcoxon two-sample test.

c

Limited to facilities at which home dialysis is offered.

Figure 1.

Figure 1.

Distribution of dialysis facilities that offer home dialysis within the United States. Dialysis facilities located in urban (darker gray) counties are more likely to offer home hemodialysis (red dots) than facilities in rural (light gray).

Dialysis facility quality metrics were associated with geographic setting (Table 2). Rural facilities were more likely to have a high Dialysis Facility Compare star rating (41% versus 24% with 5 stars, P<0.001). Rural facilities also had a lower median hospitalization rate (155.1 versus 184.5 per 100 patient-years, P<0.001), a lower median readmission rate (25% versus 27% of hospital discharges, P<0.001), and a higher median fistula rate (65% versus 64%, P<0.001). Although rural facilities had fewer median nurses per facility (3 versus 4, P<0.001), they had a higher median nurse/patient ratio (0.08 versus 0.06, P<0.001). Similarly, they had fewer social workers (median 1 versus 1; there were two or more social workers at 5% of rural versus 17% of urban facilities, P<0.001), and a higher median social worker/patient ratio (0.024 versus 0.021, P<0.001).

Rural Patients Are More Likely to Have Home Dialysis as Initial Dialysis Modality

In the fully adjusted model with patient covariates only, rural patients were 16% more likely to initially begin home dialysis than urban patients were (odds ratio [OR]=1.16; 95% confidence interval [CI], 1.09 to 1.23; P<0.001; Table 3). Men (OR=0.95, 95% CI, 0.91 to 0.997; P=0.04) and older patients (OR=0.90; 95% CI, 0.88 to 0.92; per 10 years, P<0.001) were less likely to begin on home dialysis. Black patients (OR=0.65; 95% CI, 0.61 to 0.69; P<0.001), Hispanic patients (OR=0.69; 95% CI, 0.64 to 0.75; P<0.001), and those of other race and ethnicity (OR=0.87; 95% CI, 0.79 to 0.95; P=0.003) were less likely to be on home dialysis compared with White patients.

Table 3.

Patient covariates associated with home dialysis as initial dialysis modality and with switching to home dialysis

Home Dialysis as Initial Modality Switch to Home Dialysis within 90 days
Covariate Odds Ratio (95% Confidence Interval) P Value Odds Ratio (95% Confidence Interval) P Value
Rural geography (urban) 1.16 (1.09 to 1.23) <0.001 1.16 (1.05 to 1.29) 0.005
Men 0.95 (0.91 to 0.997) 0.04 1.11 (1.02 to 1.20) 0.02
Age (per 10 years) 0.90 (0.88 to 0.92) <0.001 0.85 (0.82 to 0.87) <0.001
Race (White)
 Black 0.65 (0.61 to 0.69) <0.001 0.64 (0.58 to 0.72) <0.001
 Hispanic 0.69 (0.64 to 0.75) <0.001 0.61 (0.53 to 0.70) <0.001
 Other 0.87 (0.79 to 0.95) 0.003 0.66 (0.55 to 0.80) <0.001
Primary disease (cystic kidney)
 Diabetes 0.59 (0.51 to 0.68) <0.001 0.74 (0.57 to 0.97) 0.03
 Glomerulonephritis 0.79 (0.68 to 0.91) 0.001 1.02 (0.77 to 1.35) 0.87
 Hypertension 0.55 (0.48 to 0.63) <0.001 0.80 (0.61 to 1.04) 0.09
 Other urologic 0.32 (0.24 to 0.42) <0.001 0.54 (0.35 to 0.84) 0.006
 Other 0.35 (0.30 to 0.41) <0.001 0.71 (0.54 to 0.95) 0.02
BMI (18.5–25 kg/m2)
 Underweight (<18.5) 0.83 (0.70 to 0.98) 0.03 0.96 (0.74 to 1.24) 0.73
 Overweight (25–30) 1.22 (1.15 to 1.30) <0.001 1.03 (0.92 to 1.16) 0.56
 Obese (≥30) 1.13 (1.06 to 1.20) <0.001 0.99 (0.89 to 1.10) 0.84
Employment (unemployed)
 Employed 2.89 (2.70 to 3.10) <0.001 2.43 (2.15 to 2.74) <0.001
 Retired 1.25 (1.17 to 1.33) <0.001 1.15 (1.03 to 1.28) 0.02
Comorbidities
 Amputation 0.69 (0.59 to 0.81) <0.001 0.87 (0.69 to 1.10) 0.24
 Atherosclerotic heart disease 0.94 (0.87 to 1.02) 0.14 0.85 (0.74 to 0.98) 0.02
 Cancer 0.91 (0.82 to 1.01) 0.08 0.82 (0.69 to 0.97) 0.02
 Congestive heart failure 0.55 (0.52 to 0.59) <0.001 0.86 (0.78 to 0.95) 0.002
 Chronic obstructive pulmonary disease 0.53 (0.47 to 0.59) <0.001 0.91 (0.79 to 1.05) 0.20
 Diabetes with insulin 0.89 (0.83 to 0.95) <0.001 0.97 (0.87 to 1.09) 0.62
 Diabetes on oral medications 1.04 (0.96 to 1.13) 0.34 0.94 (0.81 to 1.09) 0.43
 Diabetes without insulin 0.98 (0.89 to 1.08) 0.65 0.94 (0.79 to 1.11) 0.46
 Hypertension 1.11 (1.03 to 1.20) 0.01 0.95 (0.84 to 1.08) 0.42
 Peripheral vascular disease 0.78 (0.71 to 0.87) <0.001 0.98 (0.84 to 1.14) 0.75

All odds ratios from the final fully adjusted models.

Because patients often start on hemodialysis urgently, we then investigated the association between patient factors and the likelihood of switching dialysis modality within 90 days. A total of 4019 (5%) switched to home dialysis modalities within 90 days of dialysis initiation. From facilities that offered home dialysis, rural patient geography was associated with switching dialysis modality within 90 days (OR=1.16; 95% CI, 1.05 to 1.29; P=0.005; Table 3). As with the initial dialysis modality, Black patients (OR=0.64; 95% CI, 0.58 to 0.72; P<0.001), Hispanic patients (OR=0.61; 95% CI, 0.53 to 0.70; P<0.001), and those of other race and ethnicity (OR=0.66; 95% CI, 0.55 to 0.80; P<0.001) were less likely to switch dialysis modalities.

We then performed two sensitivity analyses. First, we examined the relationships with the likelihood of switching modality after 90 days (Table 3). These were generally the same direction and magnitude as those who started on home dialysis; that is, typically younger patients of higher socioeconomic status with fewer comorbidities. Second, we also examined the stable dialysis modality at 90 days so that successful early home dialysis starts would be included (Supplemental Table 1). These results, despite coming from a slightly different patient population, were largely consistent with those who started on home dialysis, underscoring the importance of starting at home.

Next, we investigated the relationship between patient and facility location; that is, how were rural patients more likely to be on dialysis if rural facilities were less likely to offer it? To test this, we limited the cohort to patients who initially started dialysis at facilities that offered home dialysis (Supplemental Table 2). In the fully adjusted model for patient and facility characteristics, we found that patients whose initial facility was in a different geography than their own were more likely to be on home dialysis: compared with urban patients at an urban facility, both the rural patients at an urban facility (OR=2.74; 95% CI, 2.46 to 3.05; P<0.001) and urban patients at a rural facility (OR=1.36; 95% CI, 1.05 to 1.77; P=0.02) were more likely to be on home dialysis.

Rural Patients Have Worse Survival on Dialysis

We then investigated patient mortality after the initiation of dialysis. In the first model, rural patients had higher mortality (adjusted hazard ratio [aHR]=1.05, 95% CI, 1.01 to 1.09; P=0.03). After demonstrating worse overall survival for patients from rural areas, we then accounted for the geographic locations of both patient and dialysis facility to establish if rural patients who go to an urban facility also gain the same survival advantage (Table 4). Unfortunately, this did not prove to be true for rural patients no matter where they underwent dialysis: rural patients who visited an urban facility still had worse overall survival (aHR=1.10, 95% CI, 1.02 to 1.19; P=0.02) compared with urban patients who remained at urban facilities, and rural patients who dialyzed at a rural facility also had worse overall survival (aHR=1.05; 95% CI, 1.003 to 1.09; P=0.04). Urban patients who visited rural facilities had similar survival to the urban patients who remained at urban facilities (aHR=1.12; 95% CI, 0.98 to 1.28; P=0.11). To establish if rural patients at urban facilities fared worse than urban patients at rural facilities, we ran the model with urban patient at rural facilities as the reference group: the aHR was 0.99 (95% CI, 0.85 to 1.15; P=0.84), making an association difficult to establish, given the relatively few urban patients who were at rural facilities.

Table 4.

Patient mortality after dialysis initiation

Patient and Facility Location
Covariate Hazard Ratio (95% Confidence Interval) P Value
Patient-level
 Geography (urban patient visits urban facility)
  Rural patient visits rural facility 1.05 (1.003 to 1.09) 0.04
  Rural patient visits urban facility 1.10 (1.02 to 1.19) 0.02
  Urban patient visits rural facility 1.12 (0.98 to 1.28) 0.11
 Men 1.00 (0.97 to 1.03) 0.85
 Age (per 10 years) 1.39 (1.37 to 1.41) <0.001
 Race (White)
  Black 0.74 (0.72 to 0.77) <0.001
  Hispanic 0.66 (0.63 to 0.70) <0.001
  Other 0.58 (0.54 to 0.63) <0.001
 Primary disease (cystic kidney disease)
  Diabetes 1.92 (1.60 to 2.30) <0.001
  Glomerulonephritis 1.75 (1.45 to 2.12) <0.001
  Hypertension 1.99 (1.66 to 2.39) <0.001
  Other urologic 2.01 (1.62 to 2.49) <0.001
  Other 3.19 (2.66 to 3.83) <0.001
 BMI (18.5–25 kg/m2)
  Underweight (<18.5) 1.31 (1.22 to 1.40) <0.001
  Overweight (25–30) 0.83 (0.80 to 0.86) <0.001
  Obese (≥30) 0.81 (0.78 to 0.84) <0.001
 Employment (unemployed)
  Employed 0.53 (0.49 to 0.58) <0.001
  Retired 1.04 (1.00 to 1.08) 0.03
 Initial modality (in-center dialysis)
  Home dialysis 0.61 (0.56 to 0.65) <0.001
 Comorbidities
  Amputation 1.42 (1.33 to 1.53) <0.001
  Atherosclerotic heart disease 1.06 (1.02 to 1.10) 0.005
  Cancer 1.22 (1.17 to 1.28) <0.001
  Congestive heart failure 1.44 (1.39 to 1.48) <0.001
  Chronic obstructive pulmonary disease 1.28 (1.23 to 1.33) <0.001
  Diabetes with insulin 1.12 (1.08 to 1.16) <0.001
  Diabetes on oral medications 0.93 (0.88 to 0.97) 0.002
  Diabetes without insulin 0.92 (0.87 to 0.98) 0.006
  Hypertension 0.79 (0.76 to 0.82) <0.001
  Peripheral vascular disease 1.16 (1.11 to 1.21) <0.001
Facility-level
 Facility size (≤10 stations)
  Medium (11–30 stations) 0.91 (0.86 to 0.96) <0.001
  Large (>30 stations) 0.93 (0.86 to 1.002) 0.06
 For-profit (nonprofit) 1.05 (1.00 to 1.11) 0.08
 Dialysis chain (independent)
  Large chain 0.95 (0.91 to 0.99) 0.03
  Small/regional chain 0.95 (0.90 to 1.00) 0.07
 Five Star rating (1 star)
  2 stars 0.76 (0.69 to 0.83) <0.001
  3 stars 0.68 (0.63 to 0.73) <0.001
  4 stars 0.65 (0.60 to 0.71) <0.001
  5 stars 0.58 (0.53 to 0.63) <0.001
 Offers home hemodialysis training 0.97 (0.94 to 1.00) 0.08
 Total patients at beginning of year (per 10 patients) 1.00 (0.99 to 1.00) 0.11
 Percentage of patients on home dialysis 1.00 (1.00 to 1.00) 0.45
 Nurse/patient ratio (per 10 nurses) 1.00 (0.98 to 1.02) 0.75
 Social worker/patient ratio (per 10 social workers) 1.00 (0.99 to 1.00) 0.55

Patients whose initial dialysis modality was at home were at significantly lower risk of death (aHR=0.61; 95% CI, 0.56 to 0.65; P<0.001). Mortality was not different for patients on either home hemodialysis or peritoneal dialysis (aHR=1.06; 95% CI, 0.85 to 1.32; P=0.59; data not shown in table), so the categories were maintained as home dialysis versus in-center hemodialysis. Mortality was lower among Black patients (aHR=0.74; 95% CI, 0.72 to 0.77; P<0.001), Hispanic patients (aHR=0.66; 95% CI, 0.63 to 0.70; P<0.001), and those of another race and ethnicity (aHR 0.58; 95% CI, 0.54 to 0.63; P<0.001). Compared with patients at small facilities, medium-sized facilities were associated with lower mortality (aHR=0.91; 95% CI, 0.86 to 0.96; P<0.001), but large facilities were not (aHR=0.93; 95% CI, 0.86 to 1.002; P=0.06). Finally, higher Dialysis Facility Compare star ratings were also associated with lower mortality (for five stars versus one star: aHR=0.58; 95% CI, 0.53 to 0.63; P<0.001).

Discussion

In this study, we examined the relative contributions of both patient and dialysis facility rurality in the treatment of ESKD. Although rural patients had a 13% higher utilization of home dialysis as initial modality, there were 5% fewer facilities that offer peritoneal dialysis in rural counties. The increased utilization of home dialysis by rural patients is driven by starting at urban facilities where they could access peritoneal dialysis, where they were 2.74 times more likely to be on home dialysis. The fact that patients who already suffer from geographic disparities need to travel outside of their communities to fulfill the goals of AAKH is worth considering for future policy and incentives.

We then investigated what factors were associated with switching dialysis modality within 90 days of initiation. Many patients start on hemodialysis abruptly (“crash onto dialysis”) and later have the chance to convert to more permanent access, either via peritoneal dialysis or using a permanent fistula. The patients most likely to switch were younger, employed, and White. Because these patients are under the care of the dialysis center rather than their pre-ESKD nephrologists, this both emphasizes and measures the role the dialysis centers have in assisting patients to change modality before the incentives attached to AAKH. Future policy and reimbursement incentives could also examine this metric: changing modalities after initially starting on home dialysis, which could be designed to encourage a broader consideration of home dialysis approaches.

Access to high-quality care for rural patients is generally felt to be inferior to that of urban patients, but that does not appear to be true for dialysis facilities. Rural facilities had a higher Dialysis Facility Compare star rating, a lower hospitalization rate, and a lower readmission rate. These better-quality ratings were achieved in the setting of relatively fewer resources but with a better nurse/patient ratio and a better patient/social worker ratio; this could have to do with either differences among case mix and severity/different patient populations (17,18) or market competition (1921) among different dialysis centers because they serve different patient populations. The lower-quality ratings for the urban centers could be explained by the different staffing, but the difference in mortality requires further investigation.

Despite the higher quality of the rural dialysis facilities, the mortality after initiation of dialysis is higher for rural patients. Although mortality clearly does not fall entirely on the dialysis facility, it underlines the health care disparities experienced by rural patients in the United States and therefore what patient outcomes are really appropriate for rural dialysis facilities to be held accountable for. Unfortunately, rural patients visiting an urban facility did not confer the same survival benefit that urban patients have. This makes the problem significantly more complex because it would not be expected that simply increasing the number of home dialysis–providing units would improve mortality. Perhaps different resource allocation and priority, especially toward caring for such an ill population, is the best way to improve the overall mortality of these patients.

The economic incentives attached to AAKH to increase the utilization of home dialysis will likely increase the availability of home dialysis at different facilities; whether this will happen somewhat randomly or be focused on specific geographic areas is unknown. It is tempting to speculate on the broader economic effects of this increase in home dialysis use, especially if more rural facilities offered home dialysis methods. In that hypothetical case, travel would likely decrease and patient experience and quality of care would likely improve, but fully estimating these effects is outside of the scope of the current study, given the uncertain future course. Additionally, incentivizing small rural facilities could have the unintended consequence of reducing individual facility expertise, which may expose patients to higher risks of technique failure (22).

Our analysis is limited by its retrospective nature, which cannot establish causal relationships. There is not a reliable way to account for why patients end up at a particular dialysis facility or why they change modalities, but there is evidence from this study, others in literature, and those in access to transplantation that the dialysis facility itself played a significant role in care and outcomes for these patients (2326). Additionally, the role of distance (27,28) and the social determinants of health (17,21,29) could not be fully accounted for with the data available in the USRDS, and certainly represent areas of future study.

In conclusion, rural patients on dialysis face barriers in accessing home dialysis, and they do so by accessing urban dialysis facilities. Despite the challenges imposed by distance, these patients generally overcome it by getting to a facility in an urban county that offers home dialysis methods. Further policy would benefit from increasing access to home dialysis for rural patients, and to consider candidates for home dialysis more broadly.

Disclosures

J.T. Adler reports honoraria from CareDx. S.A. Husain reports research funding from the Nelson Family Foundation and honoraria from the Renal Research Institute. S.S. Waikar reports consultancy for Allena, BioMarin, CVS, GSK, JNJ, Mallinckrodt, Mass Medical International, Metro Biotechnology, Oxidien, Roth Capital Partners, Pfizer, Regeneron, Sironax, Strataca/3ive, Venbio, and Wolters Kluewer; research funding from Vertex; being on the scientific advisory board for Kantum; and being an expert witness for litigation related to GE product Omniscan, being an expert witness for litigation related to Fresenius product Granuflo, being an expert witness for litigation involving cisplatin toxicity, being an expert witness for litigation related to Gilead product tenofovir, and being an expert witness for litigation related to DaVita lab testing. The remaining authors have nothing to disclose.

Funding

This work was funded by the American Society of Transplant Surgeons-CareDx Enhancing Organ Donation and Transplantation grant.

Author Contributions

J.T. Adler, J.R. Rodrigue, and S.S. Waikar conceptualized the study; J.T. Adler curated the data and was responsible for funding acquisition, project administration, resources, and software; J.T. Adler, S.A. Husain, and L. Xiang were responsible for the investigation and methodology; J.T. Adler and S.A. Husain were responsible for visualization and wrote the original draft of the manuscript; and all authors were responsible for the formal analysis and for reviewing and editing the manuscript.

Data Sharing Statement

Data cannot be shared. This is secondary analysis of a publicly available dataset, but the data use agreement would prohibit direct sharing of the data.

Supplemental Material

This article contains the following supplemental material online at http://kidney360.asnjournals.org/lookup/suppl/doi:10.34067/KID.0006932021/-/DCSupplemental.

Supplemental Table 1

Patient covariates associated with stable home dialysis after 90 days. Download Supplemental Table 1, PDF file, 110 KB (109.9KB, pdf)

Supplemental Table 2

Covariates associated with home dialysis as initial modality. Download Supplemental Table 2, PDF file, 110 KB (109.9KB, pdf)

Supplemental Data

References

  • 1.The White House: Executive Order on Advancing American Kidney Health . Available at: https://www.whitehouse.gov/presidential-actions/executive-order-advancing-american-kidney-health/. Accessed March 13, 2020
  • 2.Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Castro S, Foutz J, Wainright JL, Snyder JJ, Kasiske BL, Israni AK: OPTN/SRTR 2018 annual data report: Kidney. Am J Transplant 20: 20–130, 2020. 10.1111/ajt.15672 [DOI] [PubMed] [Google Scholar]
  • 3.Mendu ML, Tummalapalli SL, Lentine KL, Erickson KF, Lew SQ, Liu F, Gould E, Somers M, Garimella PS, O’Neil T, White DL, Meyer R, Bieber SD, Weiner DE: Measuring quality in kidney care: An evaluation of existing quality metrics and approach to facilitating improvements in care delivery. J Am Soc Nephrol 31: 602–614, 2020. 10.1681/ASN.2019090869 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Patzer RE, McClellan WM: Influence of race, ethnicity and socioeconomic status on kidney disease. Nat Rev Nephrol 8: 533–541, 2012. 10.1038/nrneph.2012.117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Harding K, Mersha TB, Pham PT, Waterman AD, Webb FA, Vassalotti JA, Nicholas SB: Health disparities in kidney transplantation for African Americans. Am J Nephrol 46: 165–175, 2017. 10.1159/000479480 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Murphy KA, Jackson JW, Purnell TS, Shaffer AA, Haugen CE, Chu NM, Crews DC, Norman SP, Segev DL, McAdams-DeMarco MA: Association of socioeconomic status and comorbidities with racial disparities during kidney transplant evaluation. Clin J Am Soc Nephrol 15: 843–851, 2020. 10.2215/CJN.12541019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Stewart DE, Wilk AR, Toll AE, Harper AM, Lehman RR, Robinson AM, Noreen SA, Edwards EB, Klassen DK: Measuring and monitoring equity in access to deceased donor kidney transplantation. Am J Transplant 18: 1924–1935, 2018. 10.1111/ajt.14922 [DOI] [PubMed] [Google Scholar]
  • 8.Basu S, Berkowitz SA, Phillips RL, Bitton A, Landon BE, Phillips RS: Association of primary care physician supply with population mortality in the United States, 2005–2015. JAMA Intern Med 179: 506–514, 2019. 10.1001/jamainternmed.2018.7624 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Johnston KJ, Wen H, Joynt Maddox KE: Lack of access to specialists associated with mortality and preventable hospitalizations of rural Medicare beneficiaries. Health Aff (Millwood) 38: 1993–2002, 2019. 10.1377/hlthaff.2019.00838 [DOI] [PubMed] [Google Scholar]
  • 10.Gong G, Phillips SG, Hudson C, Curti D, Philips BU: Higher US rural mortality rates linked to socioeconomic status, physician shortages, and lack of health insurance. Health Aff (Millwood) 38: 2003–2010, 2019. 10.1377/hlthaff.2019.00722 [DOI] [PubMed] [Google Scholar]
  • 11.Lew SQ, Sikka N: Operationalizing telehealth for home dialysis patients in the United States. Am J Kidney Dis 74: 95–100, 2019. 10.1053/j.ajkd.2019.01.023 [DOI] [PubMed] [Google Scholar]
  • 12.Sloan CE, Coffman CJ, Sanders LL, Maciejewski ML, Lee S-YD, Hirth RA, Wang V: Trends in regional supply of peritoneal dialysis in an era of health reform, 2006 to 2013. Med Care Res Rev 78: 281–290, 2021. 10.1177/1077558720910633 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Prakash S, Coffin R, Schold J, Lewis SA, Gunzler D, Stark S, Howard M, Rodgers D, Einstadter D, Sehgal AR: Travel distance and home dialysis rates in the United States. Perit Dial Int 34: 24–32, 2014. 10.3747/pdi.2012.00234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Maripuri S, Arbogast P, Ikizler TA, Cavanaugh KL: Rural and micropolitan residence and mortality in patients on dialysis. Clin J Am Soc Nephrol 7: 1121–1129, 2012. 10.2215/CJN.10831011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Axelrod DA, Guidinger MK, Finlayson S, Schaubel DE, Goodman DC, Chobanian M, Merion RM: Rates of solid-organ wait-listing, transplantation, and survival among residents of rural and urban areas. JAMA 299: 202–207, 2008. 10.1001/jama.2007.50 [DOI] [PubMed] [Google Scholar]
  • 16.Center for Medicare and Medicaid Services : Medicare dialysis facility compare. Available at: https://www.medicare.gov/dialysisfacilitycompare/. Accessed August 16, 2020
  • 17.Qi AC, Butler AM, Joynt Maddox KE: The role of social risk factors in dialysis facility ratings and penalties under a Medicare quality incentive program. Health Aff (Millwood) 38: 1101–1109, 2019. 10.1377/hlthaff.2018.05406 [DOI] [PubMed] [Google Scholar]
  • 18.Tangri N, Tighiouart H, Meyer KB, Miskulin DC: Both patient and facility contribute to achieving the Centers for Medicare and Medicaid Services’ pay-for-performance target for dialysis adequacy. J Am Soc Nephrol 22: 2296–2302, 2011. 10.1681/ASN.2010111137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Erickson KF, Zheng Y, Winkelmayer WC, Ho V, Bhattacharya J, Chertow GM: Consolidation in the dialysis industry, patient choice, and local market competition. Clin J Am Soc Nephrol 12: 536–545, 2017. 10.2215/CJN.06340616 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lee DKK, Chertow GM, Zenios SA: Reexploring differences among for-profit and nonprofit dialysis providers. Health Serv Res 45: 633–646, 2010. 10.1111/j.1475-6773.2010.01103.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Erickson KF, Zheng Y, Ho V, Winkelmayer WC, Bhattacharya J, Chertow GM: Market competition and health outcomes in hemodialysis. Health Serv Res 53: 3680–3703, 2018. 10.1111/1475-6773.12835 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yao YH, Chen CM, Chou YJ, Huang N: Impact of time-varying center volume on technique failure and mortality in peritoneal dialysis. Perit Dial Int 41: 569–577, 2021. 10.1177/0896860820940449 [DOI] [PubMed] [Google Scholar]
  • 23.Patzer RE, Plantinga L, Krisher J, Pastan SO: Dialysis facility and network factors associated with low kidney transplantation rates among United States dialysis facilities. Am J Transplant 14: 1562–1572, 2014. 10.1111/ajt.12749 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Plantinga LC, Pastan SO, Wilk AS, Krisher J, Mulloy L, Gibney EM, Patzer RE: Referral for kidney transplantation and indicators of quality of dialysis care: A cross-sectional study. Am J Kidney Dis 69: 257–265, 2017. 10.1053/j.ajkd.2016.08.038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.King KL, Husain SA, Schold JD, Patzer RE, Reese PP, Jin Z, Ratner LE, Cohen DJ, Pastan SO, Mohan S: Major variation across local transplant centers in probability of kidney transplant for wait-listed patients. J Am Soc Nephrol 31: 2900–2911, 2020. 10.1681/ASN.2020030335 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.McPherson LJ, Barry V, Yackley J, Gander JC, Pastan SO, Plantinga LC, Paul S, Patzer RE; Southeastern Kidney Transplant Coalition : Distance to kidney transplant center and access to early steps in the kidney transplantation process in the southeastern United States. Clin J Am Soc Nephrol 15: 539–549, 2020. 10.2215/CJN.08530719 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Stephens JM, Brotherton S, Dunning SC, Emerson LC, Gilbertson DT, Harrison DJ, Kochevar JJ, McClellan AC, McClellan WM, Wan S, Gitlin M: Geographic disparities in patient travel for dialysis in the United States. J Rural Health 29: 339–348, 2013. 10.1111/jrh.12022 [DOI] [PubMed] [Google Scholar]
  • 28.Pattharanitima P, El Shamy O, Chauhan K, Saha A, Wen HH, Sharma S, Uribarri J, Chan L: The association between prevalence of peritoneal dialysis vs hemodialysis and patients’ distance to dialysis-providing facilities. Kidney360 2: 1908–1916, 2021. 10.34067/KID.0004762021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Årestedt L, Martinsson C, Hjelm C, Uhlin F, Eldh AC: Patient participation in dialysis care—A qualitative study of patients’ and health professionals’ perspectives. Health Expect 22: 1285–1293, 2019. 10.1111/hex.12966 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Table 1

Patient covariates associated with stable home dialysis after 90 days. Download Supplemental Table 1, PDF file, 110 KB (109.9KB, pdf)

Supplemental Table 2

Covariates associated with home dialysis as initial modality. Download Supplemental Table 2, PDF file, 110 KB (109.9KB, pdf)

Supplemental Data

Articles from Kidney360 are provided here courtesy of American Society of Nephrology

RESOURCES